期刊
JOURNAL OF CLINICAL PHARMACOLOGY
卷 52, 期 4, 页码 464-474出版社
WILEY
DOI: 10.1177/0091270011399577
关键词
mu-Opioid receptor; pharmacokinetics; food intake; taste preference; hedonic; reward; pharmacodynamic; obesity; binge eating
资金
- GlaxoSmithKline (GSK) Pharmaceuticals
Endogenous opioids and mu-opioid receptors have been linked to hedonic and rewarding aspects of palatable food intake. The authors examined the safety, pharmacokinetic, and pharmacodynamic profile of GSK1521498, a mu-opioid receptor inverse agonist that is being investigated primarily for the treatment of overeating behavior in obesity. In healthy participants, GSK1521498 oral solution and capsule formulations were well tolerated up to a dose of 100 mg. After single doses (10-150 mg), the maximum concentration (C-max) and area under the curve (AUC) in plasma increased in a dose-proportional manner. GSK1521498 selectively reduced sensory hedonic ratings of high-sugar and high-fat dairy products and caloric intake of high-fat/high-sucrose snack foods. These findings provide encouraging data in support of the development of GSK1521498 for the treatment of disorders of maladaptive ingestive behavior or compulsive consumption.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据